Taiho Ventures, LLC
Corporate VCMenlo Park · Seed–Series B · 6 people tracked
Investment thesis
Taiho Ventures aims to generate significant value by investing in the global biotech venture ecosystem while sourcing innovative science to benefit its parent company, Taiho Pharmaceutical Co., Ltd. As a corporate venture arm, it focuses on biotechnology and life-science innovation with a global mandate, connecting cutting-edge research and emerging companies to the strategic interests of the pharmaceutical parent.
Source: firm website, verified Aug 3, 2026.
Team · 6 people
from the firm's website & public directories
What they invest in
from 24 of 26 portfolio companiesBiotech ×24Medical Devices ×10Healthtech ×9AI & Machine Learning ×5Deep Tech ×2Digital Health ×1Longevity ×1
HQs:United States×12Japan×1Netherlands×1
Who they back
founder profiles across 8 portfolio companiesFounding team size:solo founder×32 founders×13 founders×34+ founders×1
Investments · 26 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 22020 · 25 dated
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BiotechBeltsville, US
Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)Udayan Guha(Executive Officer)Steven P. Cobourn(Executive Officer)Sourav Kundu(Executive Officer)Kevin Shaw(Executive Officer)
Co-investorsBay City CapitalCanaan PartnersLAVLilly Asia VenturesPfizer Venture InvestmentsQuan Capital+2 more
ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance.
BiotechHealthtechSouth San Francisco, US
Richard Heyman(Chairman, Founder, Scientific Advisory Board)Charles Sawyers(Founder, Scientific Advisory Board)Scott Lowe(Founder, Scientific Advisory Board)Jacob M. Chacko(Executive Officer, Director)Dominic Piscitelli(Chief Financial Officer)Pratik Multani(Chief Medical Officer)
Co-investorsEcoR1 CapitalNew Enterprise Associates (NEA)Nextech InvestThe Column Group
Anavo Therapeutics is a biopharmaceutical company using its IGNITE platform to develop phosphatase-targeted allosteric modulators, addressing drug targets previously considered undruggable.
BiotechHealthtechLeiden, NL
Birgit Zech(CEO)
Co-investorsBioqube VenturesInkefM Ventures
Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.
BiotechHealthtech
Rachel Humphrey(Founding Chief Executive Officer)Lieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)William LaRochelle(Chief Scientific Officer)Stacy M. Plum(Chief Technology Officer)
Co-investorsSanofi VenturesPfizer VenturesSamsara BioCapitalCanaan PartnersConnecticut InnovationsPfizer Venture Investments+3 more
Theolytics develops systemically deliverable immunotherapies based on oncolytic adenoviruses designed to target solid tumours and their supporting microenvironment.
BiotechHealthtech
Co-investorsEpidarex CapitalOxford Science EnterprisesSound BioventuresM Ventures
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical DevicesFoster City, US
Nenad Tomasevic(Executive Officer, Director)
BoardIvan Trifunovich(Director)John Wesley(Director)
Board seatSakae Asanuma· per SEC Form D
Co-investors8VCAisling CapitalMission Bay CapitalMission BiocapitalOlive Tree CapitalSR One Capital Management+1 more
BiotechBoston, US
Darlene Deptula-Hicks(Executive Officer)Rachel Humphrey(Officer and a Manager)Scott Phillips(Executive Officer)
BoardDavid Parry(Manager)Sara Nayeem(Manager)Timothy Shannon(Manager)
Board seatSakae Asanuma· per SEC Form D · $75M raise · filed Jan 2025
Arcus Biosciences develops combination cancer therapies, producing small molecules and antibodies designed to be combined and advanced from Phase 1 studies through commercialization.
Biotech
Juan Jaen(Founder)in
Co-investorsAisling CapitalDecheng CapitalDroia VenturesEcoR1 CapitalForesite CapitalSLVC+2 more
Breakpoint Therapeutics develops cancer treatments based on modulating DNA damage response pathways.
BiotechMedical Devices
cellvie develops Therapeutic Mitochondria Transplantation, a technique that augments or replaces failing mitochondria to restore cellular energy metabolism, with initial applications in ischemia-reperfusion injury (starting with kidney transplantation) and in mitochondria-enabled gene therapy for the genetic skin disease Epidermolysis Bullosa.
BiotechLongevityMedical Devices
Co-investorsBeiersdorf Innovation Fund
Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in
BoardAlexandra Cantley(Director)inSakae Asanuma(Director)inBriggs Morrison(Executive Officer, Director, Promoter)inIrena Melnikova(Director)in
Co-investorsMPM BioImpactPfizer Venture InvestmentsBiotechnology Value FundMirae Asset Venture InvestmentPfizer VenturesPolaris Partners
Cullinan Therapeutics develops clinical-stage T cell engager therapies targeting autoimmune diseases and cancer, leveraging immune modulation expertise to advance high-impact therapeutic candidates.
BiotechDigital Health
Co-investorsLAVLilly Asia VenturesMPM BioImpactSchooner Capital
Delphia Therapeutics is a biotechnology company developing cancer medicines based on its activation lethality platform, aiming to create therapies effective on their own while combating resistance to targeted therapies.
BiotechHealthtechCambridge, US
Kevin Marks(Founder)
Co-investorsGV (Google Ventures)Nextech InvestAlexandria
Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
BiotechMedical DevicesSan Mateo, US
Ann Lee-Karlon(Executive Officer, Director)Mitchell Mutz(Executive Officer, Director)James Wells(Director)
BoardSamuel Bjork(Director)Alexandra Cantley(Director)Seiji Miyahara(Director)
Co-investorsAvego BioScience CapitalGV (Google Ventures)Mission BiocapitalNovartis Venture FundRoche Venture FundSamsara BioCapital+3 more
BiotechMedical DevicesNew Haven, US
Scott Phillips(Executive Officer)
BoardTim Shannon(Manager)inLiam Ratcliffe(Manager)in
Co-investorsAccess BiotechnologyCanaan PartnersConnecticut InnovationsFrazier Life SciencesRA CapitalVida Ventures
BiotechSouth San Francisco, US
Luke Nathaniel Walker(Executive Officer)Julie Eastland(Executive Officer, Director)
BoardRonald Hunt(Director)Mark Chin(Director)Alan Colowick(Director)Jonathan Drachman(Director)
Co-investorsK2 HealthVenturesMPM BioImpact
Cambridge, MA biotech developing engineered tRNA "protein editing" therapeutics for nonsense-mutation diseases; reported shut down in 2025.
Cambridge, US
Leslie J Williams(Executive Officer, Director)
BoardBenjamin Chen(Director)Seiji Miyahara(Director)Sacha Mann(Director)David Moskowitz(Director)Steven Gillis(Director)in
Co-investorsARCH Venture Partners8VCTakeda Ventures
Light Horse Therapeutics is a small molecule drug discovery company that uses proprietary precision gene editing and target-agnostic functional screens to identify functionally critical drug targets and develop small molecule drugs against them.
AI & Machine LearningBiotech
Magnet Biomedicine develops TrueGlue™, a molecular glue discovery platform for designing small molecule therapeutics that induce novel protein-protein interactions to treat cancer and immune disorders.
AI & Machine LearningBiotechMedical Devices
Benjamin F. Cravatt, PhD(Founder & Advisor)David A. Spiegel, MD, PhD(Founder & Advisor)Michael Rosbash, PhD(Founder & Advisor)Richa Saxena, PhD(Founder & Advisor)Stuart Schreiber, PhD(Founder & Advisor)
Co-investorsARCH Venture PartnersNewpath Partners
Orna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications.
AI & Machine LearningBiotechMedical Devices
Joe Bolen(Chief Executive Officer)Joe Bolen, Ph.D.(Chief Executive Officer)Hope D'Oyley-Gay, JD(Chief Legal Officer)Ciaran Lawlor, Ph.D.(Chief Operating Officer)Frank Neumann, M.D., Ph.D.(Chief Medical Officer)Siva Sakhamuri(Chief Technology Officer)
Co-investorsAstellas Venture Management LLCMPM BioImpact
STORM Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target RNA modifying enzymes to reprogram cells through RNA biology.
BiotechHealthtechMedical Devices
Co-investorsFast Track InitiativeM VenturesPfizer Venture InvestmentsSeroba Life SciencesUTokyo Innovation Platform Co. Ltd.Cambridge Innovation Capital
Transition Bio applies methods from physics, chemistry, biology, and machine learning to study protein biophysics—including protein aggregation, self-assembly, and protein-protein interactions—for developing therapeutics targeting health and disease.
AI & Machine LearningBiotechDeep TechCambridge, US
Tuomas Knowles(Executive Director, Co-Founder & Chief Technology Officer)Samuel Cohen(Executive Director & Co-Founder)G. Kelly Martin(Executive Chairman & Co-Founder)George Martin(Executive Officer, Director)Stephanie Torruella(Executive Officer)Preet Makkar(Executive Officer)
Co-investorsNorthpond VenturesLifeforce CapitalMagnetic VenturesDolby Family Ventures
Vertero is a biotech company developing oral therapeutics that target peripheral drivers of neurodegenerative diseases such as Parkinson's.
BiotechHealthtech
Co-investorsUTokyo Innovation Platform Co. Ltd.
Co-investorsBreakout VenturesPfizer Venture Investments
Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer.
BiotechHealthtechMedical DevicesWatertown, US
Daniel J. Hicklin(Founder, President, Chief Executive Officer, and Board member)Luke Evnin(Co-founder, Board member (Chairman))inDaniel Hicklin(Executive Officer, Director)David Cordo(Executive Officer)Alon Lazarus(Director)
BoardChristoph Westphal(Director)
Co-investorsDC Investment PartnersK2 HealthVenturesLongwood FundMPM BioImpactRA Capital
LiberoThera is a drug discovery company using cell-free membrane protein preparation technology and non-natural amino acid incorporation technology to develop antibody-based therapeutics, including antibodies targeting GPCRs such as anti-CCR8.
BiotechDeep Tech
Co-investorsMC Healthcare VenturesUTokyo Innovation Platform Co. Ltd.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 2
IPOs and acquisitions across the tracked portfolioNextCureNASDAQ: NXTCORIC PharmaceuticalsNASDAQ: ORIC
Portfolio news
latest coverage across their companies
Arcus Biosciences · pluang.com · Aug 19, 2026
ORIC Pharmaceuticals · manilatimes.net · Aug 7, 2026
NextCure · investing.com · Jul 15, 2026
Cullinan Oncology · investing.com · Jun 23, 2026
hC Bioscience · altss.com · Jun 3, 2026
Orna · news.crunchbase.com · Feb 18, 2026
Frequently asked questions
- How many investments has Taiho Ventures, LLC made?
- Taiho Ventures, LLC has 23 tracked investments, including 1 dated in the last 24 months.
- What stage does Taiho Ventures, LLC invest at?
- Taiho Ventures, LLC invests at the Seed, Series A, Series B stages.
- What sectors does Taiho Ventures, LLC focus on?
- Taiho Ventures, LLC focuses on Biotech, Medical Devices.
- Where is Taiho Ventures, LLC located?
- Taiho Ventures, LLC is headquartered in Menlo Park, US.
- Who does Taiho Ventures, LLC co-invest with?
- Taiho Ventures, LLC most often shares deals with Pfizer Venture Investments, Canaan Partners, MPM BioImpact, among 49 tracked co-investors.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.